Cancer vaccine for lung cancer that stopped responding to immunotherapy
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a therapeutic cancer vaccine called OSE2101 for people with advanced non-small cell lung cancer whose tumors stopped responding to an immunotherapy drug. The vaccine is designed to help your immune system fight the cancer in a different way.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of lung cancer called non-small cell lung cancer that has spread to other parts of the body (stage 4).
- You must have a specific blood trait called HLA-A2. Your doctor can test for this.
- Your cancer does not have certain genetic changes that can be treated with targeted therapy (like EGFR, ALK, or ROS1).
- Your cancer stopped responding to a previous immunotherapy (such as Keytruda or Opdivo).
- You are 18 years or older.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs—telisotuzumab vedotin and osimertinib—for people with a specific type of advanced non-small cell lung cancer that has stopped responding to osimertinib alone. The goal is to see if adding the second drug can help control the cancer.
This Phase 1/2 study tests how well and how safely OSE-279 works in people with advanced non-small cell lung cancer (NSCLC) who cannot be cured with surgery or radiation. It also looks at the right dose and how it may help, especially if the tumor has high PD-L1.
This trial tests a combination of a personalized cancer vaccine, an immunotherapy drug (PD-1 inhibitor), and radiation therapy for people with advanced non-small cell lung cancer that has gotten worse after at least two prior treatments. The goal is to see if this approach can help shrink tumors or slow cancer growth.
This trial tests a combination of two drugs (cemiplimab and OSE2101) as ongoing treatment after initial chemo-immunotherapy for advanced lung cancer. It is for patients whose tumor DNA is still detectable in the blood, and who carry a specific immune marker called HLA-A2.
This trial tests a personalized cancer vaccine, alone or with toripalimab (a drug that helps your immune system fight cancer), in people with non-small cell lung cancer (NSCLC) that was removed by surgery. It aims to see if the vaccine is safe and could help prevent the cancer from coming back.
This trial tests a combination of a personalized vaccine (made from your tumor's unique markers), a drug that boosts your immune system (PD-1 inhibitor), and targeted radiation for people with advanced lung cancer that has progressed after initial treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Hear when a new Patients With Non-Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.